CA2754028A1 - Identification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez - Google Patents
Identification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez Download PDFInfo
- Publication number
- CA2754028A1 CA2754028A1 CA2754028A CA2754028A CA2754028A1 CA 2754028 A1 CA2754028 A1 CA 2754028A1 CA 2754028 A CA2754028 A CA 2754028A CA 2754028 A CA2754028 A CA 2754028A CA 2754028 A1 CA2754028 A1 CA 2754028A1
- Authority
- CA
- Canada
- Prior art keywords
- jak2
- patients
- mutation
- cells
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000037244 polycythemia vera Diseases 0.000 title claims description 27
- 208000017733 acquired polycythemia vera Diseases 0.000 title claims description 25
- 206010072206 Janus kinase 2 mutation Diseases 0.000 title description 6
- 102200087780 rs77375493 Human genes 0.000 claims abstract description 119
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 claims abstract description 95
- 238000000034 method Methods 0.000 claims description 59
- 208000011580 syndromic disease Diseases 0.000 claims description 20
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims description 16
- 230000002071 myeloproliferative effect Effects 0.000 claims description 15
- 208000014767 Myeloproliferative disease Diseases 0.000 claims description 14
- 238000005534 hematocrit Methods 0.000 claims description 11
- 238000000338 in vitro Methods 0.000 claims description 10
- 238000012360 testing method Methods 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 238000002965 ELISA Methods 0.000 claims description 2
- 230000027455 binding Effects 0.000 claims description 2
- 108010019437 Janus Kinase 2 Proteins 0.000 abstract description 96
- 230000035772 mutation Effects 0.000 abstract description 56
- 108090000623 proteins and genes Proteins 0.000 abstract description 52
- 102000004169 proteins and genes Human genes 0.000 abstract description 23
- 239000002773 nucleotide Substances 0.000 abstract description 22
- 125000003729 nucleotide group Chemical group 0.000 abstract description 22
- 241000124008 Mammalia Species 0.000 abstract description 8
- 150000001413 amino acids Chemical class 0.000 abstract description 2
- 238000013518 transcription Methods 0.000 abstract description 2
- 230000035897 transcription Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 84
- 108020004414 DNA Proteins 0.000 description 43
- 208000008601 Polycythemia Diseases 0.000 description 41
- 108020004459 Small interfering RNA Proteins 0.000 description 41
- 239000000523 sample Substances 0.000 description 38
- 238000001514 detection method Methods 0.000 description 37
- 238000003745 diagnosis Methods 0.000 description 27
- 230000014509 gene expression Effects 0.000 description 27
- 241001465754 Metazoa Species 0.000 description 19
- 101150009057 JAK2 gene Proteins 0.000 description 18
- 238000012163 sequencing technique Methods 0.000 description 14
- 108700019146 Transgenes Proteins 0.000 description 13
- 230000003321 amplification Effects 0.000 description 13
- 230000005764 inhibitory process Effects 0.000 description 13
- 238000003199 nucleic acid amplification method Methods 0.000 description 13
- 102000039446 nucleic acids Human genes 0.000 description 13
- 108020004707 nucleic acids Proteins 0.000 description 13
- 150000007523 nucleic acids Chemical class 0.000 description 13
- 241000282414 Homo sapiens Species 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 210000001185 bone marrow Anatomy 0.000 description 12
- 230000000925 erythroid effect Effects 0.000 description 12
- 238000009396 hybridization Methods 0.000 description 12
- 230000009261 transgenic effect Effects 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- 102000003951 Erythropoietin Human genes 0.000 description 10
- 108090000394 Erythropoietin Proteins 0.000 description 10
- 229940105423 erythropoietin Drugs 0.000 description 10
- 230000006801 homologous recombination Effects 0.000 description 10
- 238000002744 homologous recombination Methods 0.000 description 10
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 230000004069 differentiation Effects 0.000 description 9
- 238000003205 genotyping method Methods 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 108700028369 Alleles Proteins 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 210000003714 granulocyte Anatomy 0.000 description 8
- 206010028537 myelofibrosis Diseases 0.000 description 8
- 210000003924 normoblast Anatomy 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 108020004705 Codon Proteins 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 230000002269 spontaneous effect Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 206010020751 Hypersensitivity Diseases 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 208000005485 Thrombocytosis Diseases 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 238000002405 diagnostic procedure Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 5
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 5
- 108010002386 Interleukin-3 Proteins 0.000 description 5
- 102000000646 Interleukin-3 Human genes 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 108091000080 Phosphotransferase Proteins 0.000 description 5
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 5
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 208000026935 allergic disease Diseases 0.000 description 5
- 210000002459 blastocyst Anatomy 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 230000009610 hypersensitivity Effects 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 229940076264 interleukin-3 Drugs 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 102000020233 phosphotransferase Human genes 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 4
- 102100024209 CD177 antigen Human genes 0.000 description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 4
- 102100036509 Erythropoietin receptor Human genes 0.000 description 4
- 101000980845 Homo sapiens CD177 antigen Proteins 0.000 description 4
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 4
- 108091082332 JAK family Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 4
- 108010029477 STAT5 Transcription Factor Proteins 0.000 description 4
- 102100024481 Signal transducer and activator of transcription 5A Human genes 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000002449 erythroblastic effect Effects 0.000 description 4
- 238000010363 gene targeting Methods 0.000 description 4
- 230000003394 haemopoietic effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 208000013213 secondary polycythemia Diseases 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 208000031404 Chromosome Aberrations Diseases 0.000 description 3
- 108010075944 Erythropoietin Receptors Proteins 0.000 description 3
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 3
- 102000042838 JAK family Human genes 0.000 description 3
- 102000015617 Janus Kinases Human genes 0.000 description 3
- 108010024121 Janus Kinases Proteins 0.000 description 3
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 3
- 102000005763 Thrombopoietin Receptors Human genes 0.000 description 3
- 108010070774 Thrombopoietin Receptors Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 201000003948 acquired polycythemia Diseases 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 239000013599 cloning vector Substances 0.000 description 3
- 230000003021 clonogenic effect Effects 0.000 description 3
- 230000002559 cytogenic effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 230000009368 gene silencing by RNA Effects 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- 108091029865 Exogenous DNA Proteins 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 102000002001 Non-Receptor Type 6 Protein Tyrosine Phosphatase Human genes 0.000 description 2
- 108010015793 Non-Receptor Type 6 Protein Tyrosine Phosphatase Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 108010091086 Recombinases Proteins 0.000 description 2
- 102000018120 Recombinases Human genes 0.000 description 2
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 2
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 2
- 206010041660 Splenomegaly Diseases 0.000 description 2
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 description 2
- 101710128901 Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000006552 constitutive activation Effects 0.000 description 2
- 108010057085 cytokine receptors Proteins 0.000 description 2
- 102000003675 cytokine receptors Human genes 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 210000000267 erythroid cell Anatomy 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 206010024378 leukocytosis Diseases 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000001991 pathophysiological effect Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 102000009076 src-Family Kinases Human genes 0.000 description 2
- 108010087686 src-Family Kinases Proteins 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- BRZYSWJRSDMWLG-DJWUNRQOSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 1
- QRBLKGHRWFGINE-UGWAGOLRSA-N 2-[2-[2-[[2-[[4-[[2-[[6-amino-2-[3-amino-1-[(2,3-diamino-3-oxopropyl)amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2s,3r,4r,5s)-4-carbamoyl-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)- Chemical compound N=1C(C=2SC=C(N=2)C(N)=O)CSC=1CCNC(=O)C(C(C)=O)NC(=O)C(C)C(O)C(C)NC(=O)C(C(O[C@H]1[C@@]([C@@H](O)[C@H](O)[C@H](CO)O1)(C)O[C@H]1[C@@H]([C@](O)([C@@H](O)C(CO)O1)C(N)=O)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C QRBLKGHRWFGINE-UGWAGOLRSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010061764 Chromosomal deletion Diseases 0.000 description 1
- 108010051219 Cre recombinase Proteins 0.000 description 1
- 206010067477 Cytogenetic abnormality Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101100015729 Drosophila melanogaster drk gene Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 244000148064 Enicostema verticillatum Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 102100031939 Erythropoietin Human genes 0.000 description 1
- 101710102442 Erythropoietin receptor Proteins 0.000 description 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 102000028180 Glycophorins Human genes 0.000 description 1
- 108091005250 Glycophorins Proteins 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 description 1
- 101100233766 Homo sapiens JAK2 gene Proteins 0.000 description 1
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 description 1
- 101001113490 Homo sapiens Poly(A)-specific ribonuclease PARN Proteins 0.000 description 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
- 101000829171 Hypocrea virens (strain Gv29-8 / FGSC 10586) Effector TSP1 Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102000014429 Insulin-like growth factor Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- ZQISRDCJNBUVMM-UHFFFAOYSA-N L-Histidinol Natural products OCC(N)CC1=CN=CN1 ZQISRDCJNBUVMM-UHFFFAOYSA-N 0.000 description 1
- ZQISRDCJNBUVMM-YFKPBYRVSA-N L-histidinol Chemical compound OC[C@@H](N)CC1=CNC=N1 ZQISRDCJNBUVMM-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000907681 Morpho Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100233767 Mus musculus Jak2 gene Proteins 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- LTQCLFMNABRKSH-UHFFFAOYSA-N Phleomycin Natural products N=1C(C=2SC=C(N=2)C(N)=O)CSC=1CCNC(=O)C(C(O)C)NC(=O)C(C)C(O)C(C)NC(=O)C(C(OC1C(C(O)C(O)C(CO)O1)OC1C(C(OC(N)=O)C(O)C(CO)O1)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C LTQCLFMNABRKSH-UHFFFAOYSA-N 0.000 description 1
- 108010035235 Phleomycins Proteins 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 108010010677 Phosphodiesterase I Proteins 0.000 description 1
- 102100023715 Poly(A)-specific ribonuclease PARN Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102100039641 Protein MFI Human genes 0.000 description 1
- 208000003670 Pure Red-Cell Aplasia Diseases 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010071547 Trisomy 9 Diseases 0.000 description 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 1
- 208000031655 Uniparental Disomy Diseases 0.000 description 1
- 108010042352 Urokinase Plasminogen Activator Receptors Proteins 0.000 description 1
- 102000004504 Urokinase Plasminogen Activator Receptors Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 230000010455 autoregulation Effects 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 231100001025 bone marrow hyperplasia Toxicity 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- WZUDOUFCWWUEPP-ZIYJDXEPSA-N chembl2018414 Chemical compound CC(=O)NC(C)(C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NC(C)(C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NC(C)(C)C(=O)N1[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CSC2C(N(CCCCCC(=O)NCCCCCCOP(O)(=O)OC[C@@H]3[C@H](C[C@@H](O3)N3C(N=C(N)C=C3)=O)OP(O)(=S)OC[C@@H]3[C@H](C[C@@H](O3)N3C(N=C(N)C=C3)=O)OP(O)(=S)OC[C@@H]3[C@H](C[C@@H](O3)N3C(N=C(N)C=C3)=O)OP(O)(=S)OC[C@@H]3[C@H](C[C@@H](O3)N3C(NC(=O)C(C)=C3)=O)OP(O)(=S)OC[C@@H]3[C@H](C[C@@H](O3)N3C4=C(C(NC(N)=N4)=O)N=C3)OP(O)(=S)OC[C@@H]3[C@H](C[C@@H](O3)N3C(N=C(N)C=C3)=O)OP(O)(=S)OC[C@@H]3[C@H](C[C@@H](O3)N3C(NC(=O)C(C)=C3)=O)OP(O)(=S)OC[C@@H]3[C@H](C[C@@H](O3)N3C(N=C(N)C=C3)=O)OP(O)(=S)OC[C@@H]3[C@H](C[C@@H](O3)N3C(N=C(N)C=C3)=O)OP(O)(=S)OC[C@@H]3[C@H](C[C@@H](O3)N3C(N=C(N)C=C3)=O)OP(O)(=S)OC[C@@H]3[C@H](C[C@@H](O3)N3C(N=C(N)C=C3)=O)OP(O)(=S)OC[C@@H]3[C@H](C[C@@H](O3)N3C(N=C(N)C=C3)=O)OP(O)(=S)OC[C@@H]3[C@H](C[C@@H](O3)N3C(N=C(N)C=C3)=O)OP(O)(=S)OC[C@@H]3[C@H](C[C@@H](O3)N3C(NC(=O)C(C)=C3)=O)OP(O)(=S)OC[C@@H]3[C@H](C[C@@H](O3)N3C4=C(C(NC(N)=N4)=O)N=C3)OP(O)(=S)OC[C@@H]3[C@H](C[C@@H](O3)N3C4=C(C(NC(N)=N4)=O)N=C3)OP(O)(=S)OC[C@@H]3[C@H](C[C@@H](O3)N3C(N=C(N)C=C3)=O)OP(O)(=S)OC[C@@H]3[C@H](C[C@@H](O3)N3C(NC(=O)C(C)=C3)=O)OP(O)(=S)OC[C@@H]3[C@H](C[C@@H](O3)N3C(N=C(N)C=C3)=O)OP(O)(=S)OC[C@@H]3[C@H](C[C@@H](O3)N3C(N=C(N)C=C3)=O)O)C(=O)C2)=O)C(N)=O)CCC1 WZUDOUFCWWUEPP-ZIYJDXEPSA-N 0.000 description 1
- HJWLJNBZVZDLAQ-HAQNSBGRSA-N chembl2103874 Chemical compound C1C[C@@H](CS(=O)(=O)NC)CC[C@@H]1N(C)C1=NC=NC2=C1C=CN2 HJWLJNBZVZDLAQ-HAQNSBGRSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 238000009643 clonogenic assay Methods 0.000 description 1
- 231100000096 clonogenic assay Toxicity 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000003013 erythroid precursor cell Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 101150098203 grb2 gene Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000012750 in vivo screening Methods 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000009163 protein therapy Methods 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- -1 silencers Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000000123 temperature gradient gel electrophoresis Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000011820 transgenic animal model Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 102000009816 urokinase plasminogen activator receptor activity proteins Human genes 0.000 description 1
- 108040001269 urokinase plasminogen activator receptor activity proteins Proteins 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
- G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Plant Pathology (AREA)
- Diabetes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0411480 | 2004-10-27 | ||
| FR0411480A FR2877013A1 (fr) | 2004-10-27 | 2004-10-27 | Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez |
| CA2647086A CA2647086C (fr) | 2004-10-27 | 2005-10-26 | Identification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2647086A Division CA2647086C (fr) | 2004-10-27 | 2005-10-26 | Identification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2754028A1 true CA2754028A1 (fr) | 2006-05-04 |
Family
ID=34953071
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2754028A Abandoned CA2754028A1 (fr) | 2004-10-27 | 2005-10-26 | Identification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez |
| CA2647086A Expired - Lifetime CA2647086C (fr) | 2004-10-27 | 2005-10-26 | Identification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez |
| CA2585062A Expired - Lifetime CA2585062C (fr) | 2004-10-27 | 2005-10-26 | Identification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2647086A Expired - Lifetime CA2647086C (fr) | 2004-10-27 | 2005-10-26 | Identification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez |
| CA2585062A Expired - Lifetime CA2585062C (fr) | 2004-10-27 | 2005-10-26 | Identification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez |
Country Status (20)
| Country | Link |
|---|---|
| US (9) | US7781199B2 (enExample) |
| EP (2) | EP1692281B8 (enExample) |
| JP (3) | JP5090171B2 (enExample) |
| KR (1) | KR101203003B1 (enExample) |
| CN (1) | CN101072870B (enExample) |
| AT (1) | ATE382082T1 (enExample) |
| AU (1) | AU2005298636B2 (enExample) |
| BR (1) | BRPI0517398B8 (enExample) |
| CA (3) | CA2754028A1 (enExample) |
| DE (1) | DE602005004008T2 (enExample) |
| DK (1) | DK1692281T3 (enExample) |
| ES (1) | ES2296229T3 (enExample) |
| FR (1) | FR2877013A1 (enExample) |
| IL (1) | IL182761A0 (enExample) |
| MX (1) | MX2007005174A (enExample) |
| PL (1) | PL1692281T3 (enExample) |
| PT (1) | PT1692281E (enExample) |
| SI (1) | SI1692281T1 (enExample) |
| WO (1) | WO2006045827A1 (enExample) |
| ZA (1) | ZA200703433B (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2877013A1 (fr) * | 2004-10-27 | 2006-04-28 | Assist Publ Hopitaux De Paris | Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez |
| CN100497657C (zh) * | 2006-09-27 | 2009-06-10 | 北京大学人民医院 | 检测JAK2V617F突变的方法及其专用引物与TaqMan-MGB探针 |
| WO2008061196A2 (en) * | 2006-11-15 | 2008-05-22 | Eragen Biosciences, Inc. | Methods and kits for detecting jak2 nucleic acid |
| WO2008153900A1 (en) * | 2007-06-06 | 2008-12-18 | University Of Florida Research Foundation | Kinase inhibitor compounds |
| US20100068713A1 (en) * | 2007-07-13 | 2010-03-18 | Arkray, Inc. | Probe for detecting mutation in jak2 gene and use thereof |
| GB0820631D0 (en) * | 2008-11-11 | 2008-12-17 | London School Hygiene & Tropical Medicine | Vectors |
| ES2386514T3 (es) | 2009-07-10 | 2012-08-22 | Biotrin International Limited | Método isotérmico rápido, altamente sensible, para la detección de mutaciones puntuales y SNP |
| WO2011067373A1 (fr) * | 2009-12-04 | 2011-06-09 | Assistance Publique - Hopitaux De Paris | Methode de detection d'une polyglobulie chez un chien |
| CA2789186A1 (en) * | 2010-02-10 | 2011-08-18 | Genon Biotechnologies Oy | Dual activity kinase domains and uses thereof |
| US20120021413A1 (en) * | 2010-04-30 | 2012-01-26 | Arkray, Inc. | Method for Detecting Mutation in Exon 12 of JAK2 Gene, and Nucleic Acid Probe and Kit Therefor |
| AU2011277178B2 (en) * | 2010-07-16 | 2016-10-20 | Stichting Vumc | A method of analysing a blood sample of a subject for the presence of a disease marker |
| EP2686677B1 (en) | 2011-03-18 | 2018-10-03 | Stichting VUmc | A method of analysing a blood sample of a subject for the presence of a disease marker |
| JP2013017395A (ja) * | 2011-07-07 | 2013-01-31 | Toyobo Co Ltd | 骨髄増殖性疾患に関する遺伝子変異を検出するためのプローブおよび該プローブを用いた遺伝子変異の検出方法 |
| GB201116876D0 (en) | 2011-09-30 | 2011-11-16 | Epistem Ltd | Mutational analysis of JAK2 |
| CN103243153B (zh) * | 2012-02-10 | 2014-11-05 | 复旦大学附属华山医院 | Jak2 v617f突变的检测应用 |
| WO2014068072A1 (en) | 2012-10-31 | 2014-05-08 | Institut Gustave-Roussy | Identification, assessment and therapy of essential thrombocythemia with resistance to jak2 inhibitors |
| WO2014072487A1 (en) | 2012-11-08 | 2014-05-15 | Centre National De La Recherche Scientifique (Cnrs) | New phosphodeoxyribosyltransferase mutant enzymes and uses thereof |
| WO2014074847A1 (en) | 2012-11-09 | 2014-05-15 | The Johns Hopkins University | A genetic assay to determine prognosis in polycythemia vera patients |
| MA45504B1 (fr) | 2012-12-07 | 2021-10-29 | Geron Corp | Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives |
| US9375485B2 (en) | 2012-12-07 | 2016-06-28 | Geron Corporation | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |
| WO2014186764A1 (en) | 2013-05-16 | 2014-11-20 | Mobelisk Llc | Modular tablet case |
| WO2016097773A1 (en) | 2014-12-19 | 2016-06-23 | Children's Cancer Institute | Therapeutic iap antagonists for treating proliferative disorders |
| RU2017139122A (ru) * | 2015-04-15 | 2019-05-15 | Промедиор, Инк. | Способы лечения миелопролиферативных нарушений |
| CN107949643A (zh) | 2015-04-23 | 2018-04-20 | 奎斯特诊断投资股份有限公司 | 用于检测骨髓增殖性疾病中calr突变的方法和组合物 |
| CN116327952A (zh) * | 2015-08-04 | 2023-06-27 | 阿塞勒隆制药公司 | 用于治疗骨髓增生性病症的方法 |
| CN105441573A (zh) * | 2016-01-11 | 2016-03-30 | 武汉海吉力生物科技有限公司 | 用于检测人类jak2基因v617f突变的引物、探针及试剂盒 |
| AU2017276498A1 (en) * | 2016-06-10 | 2019-01-03 | Io Biotech Aps | CALR and JAK2 vaccine compositions |
| TWI879717B (zh) | 2017-07-28 | 2025-04-11 | 美商傑龍公司 | 治療骨髓增生不良症候群之方法 |
| CA3120704A1 (en) | 2018-11-29 | 2020-06-04 | Geron Corporation | Methods of treating myelodysplastic syndrome |
| CA3161800A1 (en) | 2019-11-18 | 2021-05-27 | Janssen Biotech, Inc. | Vaccines based on mutant calr and jak2 and their uses |
| US11691971B2 (en) | 2020-06-19 | 2023-07-04 | Incyte Corporation | Naphthyridinone compounds as JAK2 V617F inhibitors |
| US11753413B2 (en) | 2020-06-19 | 2023-09-12 | Incyte Corporation | Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| SI4175719T1 (sl) | 2020-07-02 | 2025-07-31 | Incyte Corporation | Triciklične sečninske spojine kot zaviralci jak2 v617f |
| US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
| US11958861B2 (en) | 2021-02-25 | 2024-04-16 | Incyte Corporation | Spirocyclic lactams as JAK2 V617F inhibitors |
| US12084430B2 (en) | 2022-03-17 | 2024-09-10 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6582908B2 (en) * | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| US5728536A (en) * | 1993-07-29 | 1998-03-17 | St. Jude Children's Research Hospital | Jak kinases and regulation of Cytokine signal transduction |
| AU8126694A (en) | 1993-10-26 | 1995-05-22 | Affymax Technologies N.V. | Arrays of nucleic acid probes on biological chips |
| US5747282A (en) * | 1994-08-12 | 1998-05-05 | Myraid Genetics, Inc. | 17Q-linked breast and ovarian cancer susceptibility gene |
| US5753441A (en) * | 1994-08-12 | 1998-05-19 | Myriad Genetics, Inc. | 170-linked breast and ovarian cancer susceptibility gene |
| AU6407696A (en) * | 1995-07-07 | 1997-02-10 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Method of identifying inhibitors of the jak-stat signal transduction pathway |
| US5914393A (en) * | 1995-12-05 | 1999-06-22 | Incyte Pharmaceuticals, Inc. | Human Jak2 kinase |
| FI104718B (fi) * | 1998-06-18 | 2000-03-31 | Orion Yhtymae Oyj | [[4-(2-atsido-3-metyyli-5-oksotetrahydrofuran-2-yyli)fenyyli]hydratsono]propaanidinitriili käytettäväksi referenssiaineena levosimendaanierien analyysissä |
| US6821724B1 (en) * | 1998-09-17 | 2004-11-23 | Affymetrix, Inc. | Methods of genetic analysis using nucleic acid arrays |
| CA2306446A1 (en) | 1998-09-25 | 2000-04-06 | Massachusetts Institute Of Technology | Methods and products related to genotyping and dna analysis |
| WO2001079555A2 (en) * | 2000-04-14 | 2001-10-25 | Millennium Pharmaceuticals, Inc. | Roles of jak/stat family members in tolerance induction |
| PL365565A1 (en) * | 2000-06-30 | 2005-01-10 | Pfizer Inc. | Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies |
| US20030012788A1 (en) * | 2000-07-27 | 2003-01-16 | Jean-Christophe Renauld | Method for influencing kinase pathways with IL-22 |
| US20020090622A1 (en) | 2000-08-23 | 2002-07-11 | Monisola Adeokun | Chemical compounds |
| US20050235375A1 (en) * | 2001-06-22 | 2005-10-20 | Wenqiong Chen | Transcription factors of cereals |
| WO2004063324A2 (en) | 2002-05-03 | 2004-07-29 | Gene Logic, Inc. | Canine gene microarrays |
| WO2004005481A2 (en) * | 2002-07-03 | 2004-01-15 | The Trustees Of Columbia University In The City Of New York | Methods for identifying modulators of mda-7 mediated apoptosis |
| US7537891B2 (en) * | 2002-08-27 | 2009-05-26 | Bristol-Myers Squibb Company | Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in breast cells |
| US7504211B2 (en) * | 2002-08-27 | 2009-03-17 | Bristol-Myers Squibb Company | Methods of using EPHA2 for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in breast cells |
| US20060019284A1 (en) * | 2004-06-30 | 2006-01-26 | Fei Huang | Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in lung cancer cells |
| FR2877013A1 (fr) * | 2004-10-27 | 2006-04-28 | Assist Publ Hopitaux De Paris | Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez |
| US7514229B2 (en) * | 2005-09-29 | 2009-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for diagnosing and evaluating treatment of blood disorders |
| US20070248961A1 (en) * | 2006-04-20 | 2007-10-25 | Maher Albitar | Methods for detecting mutations in JAK2 nucleic acid |
| WO2011091332A2 (en) * | 2010-01-22 | 2011-07-28 | Chromatin, Inc. | Novel centromeres and methods of using the same |
-
2004
- 2004-10-27 FR FR0411480A patent/FR2877013A1/fr active Pending
-
2005
- 2005-10-26 WO PCT/EP2005/055586 patent/WO2006045827A1/fr not_active Ceased
- 2005-10-26 US US10/580,458 patent/US7781199B2/en active Active
- 2005-10-26 DK DK05815749T patent/DK1692281T3/da active
- 2005-10-26 AU AU2005298636A patent/AU2005298636B2/en not_active Expired
- 2005-10-26 EP EP05815749A patent/EP1692281B8/fr not_active Expired - Lifetime
- 2005-10-26 AT AT05815749T patent/ATE382082T1/de active
- 2005-10-26 ES ES05815749T patent/ES2296229T3/es not_active Expired - Lifetime
- 2005-10-26 EP EP07118874A patent/EP1895000A1/fr not_active Withdrawn
- 2005-10-26 DE DE602005004008T patent/DE602005004008T2/de not_active Expired - Lifetime
- 2005-10-26 PT PT05815749T patent/PT1692281E/pt unknown
- 2005-10-26 CA CA2754028A patent/CA2754028A1/fr not_active Abandoned
- 2005-10-26 CA CA2647086A patent/CA2647086C/fr not_active Expired - Lifetime
- 2005-10-26 CN CN2005800420223A patent/CN101072870B/zh not_active Expired - Lifetime
- 2005-10-26 SI SI200530129T patent/SI1692281T1/sl unknown
- 2005-10-26 CA CA2585062A patent/CA2585062C/fr not_active Expired - Lifetime
- 2005-10-26 BR BRPI0517398A patent/BRPI0517398B8/pt active IP Right Grant
- 2005-10-26 KR KR1020077011851A patent/KR101203003B1/ko not_active Expired - Lifetime
- 2005-10-26 JP JP2007538421A patent/JP5090171B2/ja not_active Expired - Lifetime
- 2005-10-26 PL PL05815749T patent/PL1692281T3/pl unknown
- 2005-10-26 MX MX2007005174A patent/MX2007005174A/es active IP Right Grant
-
2007
- 2007-04-23 IL IL182761A patent/IL182761A0/en unknown
- 2007-04-26 ZA ZA200703433A patent/ZA200703433B/xx unknown
- 2007-11-02 US US11/934,359 patent/US7429456B2/en not_active Expired - Lifetime
-
2008
- 2008-09-19 US US12/234,616 patent/US8637235B2/en active Active
-
2009
- 2009-06-30 JP JP2009155912A patent/JP5290884B2/ja not_active Expired - Lifetime
-
2011
- 2011-08-19 US US13/213,841 patent/US8466338B2/en not_active Expired - Lifetime
-
2013
- 2013-01-11 JP JP2013003374A patent/JP6103691B2/ja not_active Expired - Lifetime
- 2013-02-15 US US13/768,709 patent/US8852931B2/en not_active Expired - Lifetime
-
2014
- 2014-01-27 US US14/164,880 patent/US10364430B2/en not_active Expired - Lifetime
-
2019
- 2019-05-29 US US16/424,976 patent/US10563200B2/en not_active Expired - Lifetime
-
2020
- 2020-01-06 US US16/734,854 patent/US11162100B2/en not_active Expired - Lifetime
-
2021
- 2021-09-29 US US17/488,839 patent/US20220042016A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1692281B1 (fr) | Identification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez | |
| EP3072964A1 (en) | Novel chimera gene atf7ip-pdgfrb for acute lymphoblastic leukemia | |
| HK1114406A (en) | Identification of a jak2 mutation involved in polycythaemia vera | |
| Class et al. | Patent application title: IDENTIFICATION OF A JAK2 MUTATION INVOLVED IN VAQUEZ POLYGLOBULIA Inventors: William Vainchenker (Paris, FR) Assistance Publique Hopitaux De Paris (Paris, FR) Igr&d Sa (Villejuif Cedex, FR) Valerie Ugo (Paris, FR) James Chloe (Montrouge, FR) Jean-Pierre Le Couedic (Champs Sur Marne, FR) Institut Gustave-Roussy (Villejuif, FR) Nicole Casadevall (Paris, FR) Universite De Versailles-St Quentin En Yvelines (Versailles, FR) Universite Paris-Sud (Orsay, FR) Assignees: Assistance Publique-Hopitaux De Paris IGR&D SA Universite Paris-Sud INSTITUT GUSTAVE ROUSSY UNIVERSITE DE VERSAILLES ST QUENTIN EN YVELINES INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) | |
| HK1094974B (en) | Identification of a jak2 mutation in polycythemia vera | |
| US20180066318A1 (en) | Methods of characterizing e-syt2 inhibitors, e-syt2 inhibitors, and methods of use | |
| Zhao | Functional studies of p62 (dok) in PDGFR signaling and p210 (bcr-abl)-induced transformation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20151006 |